Is there a role of cytoreductive surgery with HIPEC in recurrent ovarian granulosa cell tumors? An Indian cancer center experience with review of literature
Indian Journal of Cancer · 2024
DOI: 10.4103/ijc.ijc_1454_21 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Cancer, 2024. Verfasst von Mukurdipi Ray und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Cytoreduction Surgical Procedures, Granulosa Cell Tumor, Hyperthermic Intraperitoneal Chemotherapy, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Background
Granulosa cell tumors of the ovary represent the most common sex-cord stromal tumors. Though characterized by an indolent course and a good five-year survival rate, they tend to have late recurrences and subsequent poorer survival. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with recurrent granulosa cell tumors with peritoneal dissemination has not been well defined.
Methods
All patients with adult or juvenile type granulosa cell tumors who underwent cytoreductive surgery with HIPEC with 70 mg/m 2 of cisplatin for 60 minutes over a period of four years were retrospectively evaluated. We also performed a review of the literature on similar cases reported.
Results
We identified eight patients with recurrent adult granulosa cell tumors (AGCT) who fulfilled our inclusion criteria. The mean operative duration was 340 minutes, inclusive of the duration of HIPEC. Fifty percent of patients suffered from postoperative morbidity. Grade 4 morbidity was observed in one patient. At a median follow-up of 35 months, four patients experienced disease recurrence. The median disease-free survival was 10 months (range: 6–31 months) and the median overall survival was 11.5 months (range: 7–40 months).
Conclusion
Cytoreductive surgery (CRS) and HIPEC provides a unique opportunity for treating peritoneal dissemination in patients with recurrent ovarian AGCTs. This procedure is well tolerated with acceptable morbidity. Prospective studies are warranted to further elucidate the efficacy of this novel therapeutic approach in recurrent ovarian granulosa cell tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India.
- Department of Gynaecologic Oncology, All India Institute of Medical Sciences, New Delhi, India.
- Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India.
ORCID-Profile: Mukurdipi Ray, Aarthi S Jayraj, Kunal Dhall, Rambha Pandey, Suryanarayana V S Deo
Zitieren
APA
Ray, M., Jayraj, A. S., Dhall, K., Pandey, R., & Deo, S. V. S. (2024). Is there a role of cytoreductive surgery with HIPEC in recurrent ovarian granulosa cell tumors? An Indian cancer center experience with review of literature. Indian Journal of Cancer. https://doi.org/10.4103/ijc.ijc_1454_21
Vancouver
Ray M, Jayraj AS, Dhall K, Pandey R, Deo SVS. Is there a role of cytoreductive surgery with HIPEC in recurrent ovarian granulosa cell tumors? An Indian cancer center experience with review of literature. Indian Journal of Cancer. 2024. doi:10.4103/ijc.ijc_1454_21
BibTeX
@article{Ray2024,
author = {Ray, Mukurdipi and Jayraj, Aarthi S and Dhall, Kunal and Pandey, Rambha and Deo, Suryanarayana V S},
title = {Is there a role of cytoreductive surgery with HIPEC in recurrent ovarian granulosa cell tumors? An Indian cancer center experience with review of literature},
journal = {Indian Journal of Cancer},
year = {2024},
doi = {10.4103/ijc.ijc_1454_21}
}
EUVIMED